Evidence map›Paper›PMID 41144034›Full record

ReviewAnnals of hematology2025

A breast cancer patient developed γδ T-cell acute lymphoblastic leukemia after chemotherapy: a case report with literary review.

Xiaofeng Yang, Zhihua Zhang, Xue Wu, Xinhong Yang

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiaofeng YangDepartment of Pediatric Surgery, the Affiliated Hospital of Chengde Medical College, Chengde, Hebei Province, China.
Zhihua ZhangDepartment of Hematology, the Affiliated Hospital of Chengde Medical College, Chengde, Hebei Province, China.
Xue WuDepartment of Hematology, the Affiliated Hospital of Chengde Medical College, Chengde, Hebei Province, China.
Xinhong YangDepartment of Hematology, the Affiliated Hospital of Chengde Medical College, Chengde, Hebei Province, China. caccine.tumor@aliyun.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gamma delta T-cell (γδ T-cell) acute lymphoblastic leukemia(γδ T-ALL) is rare and aggressive, but secondary γδ T-ALL following breast cancer is more rare. Our case presents a patient with breast cancer, received surgical treatment and chemotherapy consisting of epirubicin and cyclophosphamide. Three years later, the patient got secondary γδ T-ALL. The chemotherapeutic agents had a significant effect on the breast cancer patient, who has an increased risk of secondary γδ T-ALL.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsNeoplasms, Second PrimaryPrecursor Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaReceptors, Antigen, T-Cell, gamma-deltaCyclophosphamideEpirubicinFemaleHumansCyclophosphamideEpirubicinReceptors, Antigen, T-Cell, gamma-deltaBreast cancerSecondary acute lymphoblastic leukemiaSecondary γδ t-cell acute lymphoblastic leukemiaT-cell acute lymphoblastic leukemia

Identifiers

PMID41144034
PMCPMC12619702

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.